Cancer Clinical Pharmacology

Authors:

Brand: OUP Oxford

ISBN: 9780192629661

834.75 zł

793.01 zł Save 41.74 zł Tax included

Lowest price within 30 days before promotion: 793.01 zł

Quantity

Product unavailable

Out of print

Notify me about new stock Enter your email address to get notifications about new stock of this product

Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description

Cancer Clinical Pharmacology provides a comprehensive account of the scientific basis of anti-cancer therapy in patients with solid tumours and haematological malignancies. An international group of experts have brought together information on the basic principles of pharmacology and tumour biology, bioanalytical aspects, pharmacokinetics, and the pharmacodynamics of anti-cancer agents. The clinical pharmacology of individual anti-cancer agents are covered, including themost important recently registered novel anti-cancer drugs. This book will prove an invaluable source of information for all trainees in oncology, haematology and internal medicine. Since cancer clinical pharmacology is a vast subject this book will be useful for all individuals involved in cancer pharmacology such as nurses, pharmacists, general pharmacologists, and cancer scientists.

Product Details

Brand OUP Oxford

Reference 83260

EAN13 9780192629661

ISBN 9780192629661

Data sheet

Publication date: 2005
Issue number: 1
Cover: hard cover
Pages count: 280
Dimensions (mm): 195 x 254
Weight (g): 729

Bio-analytical methods for anticancer drugs; Principles of pharmacokinetics; Clinical implications and mechanisms of variability in the response to anticancer agents; Drug development and study design; Pyrimidine antimetabolites; Purine analogs and antifolates; Alkylating agents; Epipodophyllotoxins; Anthracyclines; Taxanes; Vinca alkaloids; Topoisomerase I targeting agents; Platinum agents; Novel tyrosine kinase inhibitors:: focus on Imatinib and Gefitinib; Antiendoctrine drugs used in cancer treatment; The clinical application of tumour biology;